Los Angeles, Calif. — Healthcare AI company Akido has raised $60 million in Series B funding to accelerate the expansion of ScopeAI, its advanced clinical artificial intelligence system designed to dramatically improve healthcare access and capacity. The funding round was led by Oak HC/FT, with support from Greco, SNR, and existing investors including Y Combinator, Future Communities Capital, Google DeepMind’s Jeff Dean, and the Comprehensive Blood & Cancer Center.
Akido’s flagship technology, ScopeAI, is being hailed as a first-of-its-kind system that fully integrates artificial intelligence into the clinical workflow. It enables trained medical assistants to conduct patient visits guided by intelligent prompts, while ScopeAI listens, analyzes, and generates a full clinical report—including a preliminary diagnosis and treatment plan—in real time. This allows physicians to oversee multiple patient encounters while focusing their time on more complex cases, helping address the ongoing physician shortage.
“Our healthcare system is under immense strain, with over 3 billion needed visits annually but only 825 million currently available,” said Prashant Samant, Co-Founder and CEO of Akido. “ScopeAI is built to help close that gap by using AI to empower providers and expand capacity—without sacrificing quality.”
Currently deployed within Akido Care, the company’s proprietary medical network of 240 providers across 26 specialties, ScopeAI has already demonstrated promising results, including five times more face-to-face time with patients and a 96 NPS (Net Promoter Score). The new capital will fund broader deployment across the network and support entry into new markets, including a pilot program in New York City tailored to chronic disease management for rideshare and for-hire drivers.
Founded in 2015, Akido began with a mission to improve care for vulnerable populations through data science and machine learning. That foundation enabled the company to develop a rich longitudinal dataset of over 10 million patient cases, which is now used to refine ScopeAI through continuous provider feedback and reinforcement learning.
“Akido is delivering on the long-promised transformation of patient visits through AI,” said Andrew Adams, Co-Founder and Managing Partner at Oak HC/FT. “With its deep clinical dataset and a model that continues to learn and adapt, ScopeAI offers a level of accuracy and efficiency that sets it apart in the healthcare AI landscape.”
By combining a robust medical network with a continually evolving AI platform, Akido is positioned to both personalize care for individual patients and scale programs at the population level—advancing its vision of making high-quality healthcare accessible for all.
